73 related articles for article (PubMed ID: 27057601)
1. Efficacy and Safety of Nedaplatin in Advanced Breast Cancer Therapy.
Pang H; Feng T; Lu H; Meng Q; Chen X; Shen Q; Dong X; Cai L
Cancer Invest; 2016; 34(4):167-72. PubMed ID: 27057601
[TBL] [Abstract][Full Text] [Related]
2. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z
Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H
Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
[TBL] [Abstract][Full Text] [Related]
7. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
[TBL] [Abstract][Full Text] [Related]
8. Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer.
Kim JY; Ryoo HM; Bae SH; Kang BW; Chae YS; Yoon S; Baek JH; Kim MK; Lee KH; Lee SA; Song HS; Kim JG
Anticancer Res; 2015 Jun; 35(6):3531-6. PubMed ID: 26026121
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Kim YS; Sym SJ; Park SH; Park I; Hong J; Ahn HK; Park J; Cho EK; Lee WK; Chung M; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2014 Jan; 73(1):163-9. PubMed ID: 24202666
[TBL] [Abstract][Full Text] [Related]
10. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Miyazawa Y; Isozaki Y; Akanuma N; Matsubara H
Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
[TBL] [Abstract][Full Text] [Related]
11. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer.
Teramoto K; Asada Y; Ozaki Y; Suzumura Y; Nakano Y; Sawai S; Tezuka N; Inoue S; Fujino S
Cancer Chemother Pharmacol; 2012 Oct; 70(4):531-7. PubMed ID: 22864949
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
Cao W; Xu C; Lou G; Jiang J; Zhao S; Geng M; Xi W; Li H; Jin Y
Jpn J Clin Oncol; 2009 Sep; 39(9):582-7. PubMed ID: 19509000
[TBL] [Abstract][Full Text] [Related]
14. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Cassier PA; Chabaud S; Trillet-Lenoir V; Peaud PY; Tigaud JD; Cure H; Orfeuvre H; Salles B; Martin C; Jacquin JP; Agostini C; Guastalla JP; Pérol D; Bachelot T
Breast Cancer Res Treat; 2008 May; 109(2):343-50. PubMed ID: 17611792
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Zhang F; Wang Y; Wang ZQ; Sun P; Wang DS; Jiang YX; Zhang DS; Wang FH; Xu RH; Li YH
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868295
[TBL] [Abstract][Full Text] [Related]
16. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
[TBL] [Abstract][Full Text] [Related]
17. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Hatschek T; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Lindh B; Loman N; Malmberg M; Rotstein S; Söderberg M; Sundquist M; Walz TM; Hellström M; Svensson H; Aström G; Brandberg Y; Carstensen J; Fernö M; Bergh J
Breast Cancer Res Treat; 2012 Feb; 131(3):939-47. PubMed ID: 22094937
[TBL] [Abstract][Full Text] [Related]
18. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.
Yin M; Zhang H; Li H; Li X; Liu Y; Chen X; Lou G; Li K
J Surg Oncol; 2012 Feb; 105(2):206-11. PubMed ID: 21815150
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
20. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
